FIELD: biotechnology.
SUBSTANCE: use of the composition containing an amount of MASP-2 inhibiting antibody, which inhibits MASP-2-dependent complement activation when producing a drug for treating or reducing the risk of developing or reducing the severity of thrombotic microangiopathy (TMA) with background stem cell transplantation, in a subject, received allogenic transplantation of haemopoetic stem cells. MASP-2 inhibitory antibody is a monoclonal antibody against MASP-2 or its antigen-binding fragment, which selectively inhibits MASP-2 complement activation without significant inhibition of the C1q-dependent classical complement pathway.
EFFECT: invention enables to inhibit cell damage associated with MASP-2-mediated activation of an alternative complement pathway, preserving an intact immune system component, which is a classical (C1q-dependent) pathway.
16 cl, 76 dwg, 42 tbl, 43 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
| COMPOSITIONS FOR INHIBITING MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2017 |
|
RU2725958C2 |
| ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
| PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2019 |
|
RU2789389C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
| ORNITHODOROS MOUBATA AND COMPLEMENT INHIBITOR FOR TREATING COMPLEMENT-MEDIATED DISEASES OF PATIENT WITH COMPLEMENT C5 POLYMORPHISM | 2015 |
|
RU2700932C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
